Horizon Discovery Acquires Hypoxium and Launches Horizon Discovery Services
Horizon Discovery announced that it has completed the acquisition of Hypoxium Ltd to form the wholly-owned subsidiary Horizon Discovery services Ltd (HDS). The newly formed contract research organization will provide oncology translational research services that include access to Horizon’s 250+ patient-relevant human isogenic cancer cell models. Specific services include; drug profiling, novel 2D & 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction.
Based on the Cambridge Science Park since its foundation in 2007, Hypoxium, a contract research organization specializing in cell biology within the oncology therapeutic area, has used its expertise to enable biotech and pharma clients to rapidly and successfully progress their lead compounds. Dan Cowell (formerly CEO of Hypoxium) has been appointed as the new Chief Operating Officer of Horizon, and Dr Kyla Grimshaw (formerly Research Director of Hypoxium) has been appointed as Research Director of HDS.
To support internal research and development that will further expand the suite of services provided by HDS, Horizon is investing $500,000 in a two-year research program. The program will add additional assays to the X-MAN Pathways panel and format these into high-throughput and relevant in-vivo assays to be operated by Horizon’s US partner TGEN Drug Development.
The commercial terms of the acquisition are to remain confidential.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
